PT  - JOURNAL ARTICLE
AU  - Petros Perros
AU  - Miloš Žarković
AU  - Claudio Azzolini
AU  - Göksun Ayvaz
AU  - Lelio Baldeschi
AU  - Luigi Bartalena
AU  - Antonella Boschi
AU  - Claire Bournaud
AU  - Thomas Heiberg Brix
AU  - Danila Covelli
AU  - Slavica Ćirić
AU  - Chantal Daumerie
AU  - Anja Eckstein
AU  - Nicole Fichter
AU  - Dagmar Führer
AU  - Laszlo Hegedüs
AU  - George J Kahaly
AU  - Onur Konuk
AU  - Jürg Lareida
AU  - John Lazarus
AU  - Marenza Leo
AU  - Lemonia Mathiopoulou
AU  - Francesca Menconi
AU  - Daniel Morris
AU  - Onyebuchi Okosieme
AU  - Jaques Orgiazzi
AU  - Susanne Pitz
AU  - Mario Salvi
AU  - Cristina Vardanian-Vartin
AU  - Wilmar Wiersinga
AU  - Martine Bernard
AU  - Lucy Clarke
AU  - Nicola Currò
AU  - Colin Dayan
AU  - Jane Dickinson
AU  - Miroslav Knežević
AU  - Carol Lane
AU  - Claudio Marcocci
AU  - Michele Marinò
AU  - Lars Möller
AU  - Marco Nardi
AU  - Christopher Neoh
AU  - Simon Pearce
AU  - George von Arx
AU  - Fosun Baloş Törüner
TI  - PREGO (presentation of Graves’ orbitopathy) study: changes in referral patterns to European Group On Graves’ Orbitopathy (EUGOGO) centres over the period from 2000 to 2012
AID  - 10.1136/bjophthalmol-2015-306733
DP  - 2015 Nov 01
TA  - British Journal of Ophthalmology
PG  - 1531--1535
VI  - 99
IP  - 11
4099  - http://bjo.bmj.com/content/99/11/1531.short
4100  - http://bjo.bmj.com/content/99/11/1531.full
SO  - Br J Ophthalmol2015 Nov 01; 99
AB  - Background/aims The epidemiology of Graves’ orbitopathy (GO) may be changing. The aim of the study was to identify trends in presentation of GO to tertiary centres and initial management over time.Methods Prospective observational study of European Group On Graves’ Orbitopathy (EUGOGO) centres. All new referrals with a diagnosis of GO over a 4-month period in 2012 were included. Clinical and demographic characteristics, referral timelines and initial decisions about management were recorded. The data were compared with a similar EUGOGO survey performed in 2000.Results The demographic characteristics of 269 patients studied in 2012 were similar to those collected in the year 2000, including smoking rates (40.0% vs 40.2%). Mild (60.5% vs 41.2%, p<0.01) and inactive GO (63.2% vs 39.9%, p<0.01) were more prevalent in 2012. The times from diagnosis of thyroid disease to being seen in EUGOGO centres (6 vs 16 months) and from first symptoms of GO (9 vs 16 months) or from diagnosis of GO (6 vs 12 months) to first consultation in EUGOGO centres were shorter in 2012 (p<0.01). The initial management plans for GO were no different except surgical treatments for patients with mild inactive disease were more frequently offered in the 2012 cohort than in 2000 (27.3% vs 17%, p<0.05), and selenium supplements were offered only in the 2012 cohort (21.2% vs 0%, p<0.01).Conclusions These findings suggest that the clinical manifestations of patients with GO may be changing over time in Europe.